Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Patients Who Are Refractory to Ida-FLAG As Initial Induction Chemotherapy for AML Have Persistence of the Dominant Genetic Mutations and a Poor Clinical Outcome

Blood (2017) 130 (Supplement 1): 2596.

https://doi.org/10.1182/blood.V130.Suppl_1.2596.2596

Published: 2017

Journal Articles

The Utility of Early Broncholaveolar Lavage in Prolonged Neutropenic Patients with Pulmonary Nodules

Dina Khalaf, MD BSc, Steven M. Chan, MD PhD, Vikas Gupta, MD PhD, Andrzej Lutynski, MD, Dawn Maze, MD FRCPC, MSc, Mark D. Minden, MD PhD, Yoichiro Natori, MD, Rhea Pavan, BA, Amr Rostom, MD, Anna Rydlewski, MD, Aaron Schimmer, MD PhD, Andre Schuh, MD FRCPC, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Shahid Husain, MD MS

Blood (2017) 130 (Supplement 1): 4682.

https://doi.org/10.1182/blood.V130.Suppl_1.4682.4682

Published: 2017

Journal Articles

Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived

Sara Farshchi Zarabi, MD, Steven M. Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dina Khalaf, BSc, MSc, MD, Andrzej Lutynski, MD, Mark D. Minden, MD PhD, Amr Rostom, MD, Anna Rydlewski, MD, Andre C. Schuh, MD FRCPC, Hassan Sibai, MD, Karen W.L. Yee, MD, Aaron D. Schimmer, MD PhD

Blood (2016) 128 (22): 2800.

https://doi.org/10.1182/blood.V128.22.2800.2800

Published: 2016

Journal Articles

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Andre C Schuh, MD FRCPC, Mark D. Minden, MD PhD, Aaron D. Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Mohamed Shanavas, MD FRACP, FRCPA, Andrzej Lutynski, MD, Amr Rostom, MD, Anna Rydlewski, MD, Dina Khalaf, BSc, MSc, MD, Karen W.L. Yee, MD

Blood (2015) 126 (23): 4893.

https://doi.org/10.1182/blood.V126.23.4893.4893

Published: 2015

Journal Articles

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Joseph Brandwein, MD FRCPC, Vikas Gupta, MD FRCP, FRCPath, Johann Hitzler, MD FRCP (C), FAAP, Dina Khalaf, BSc, MSc, MD, Andrzej Lutynski, MD, Aaron D. Schimmer, MD PhD, Andre C Schuh, MD FRCPC, Amr Rostom, MD, Anna Rydlewski, MD, Karen W.L. Yee, MD, Mark D. Minden, MD PhD

Blood (2015) 126 (23): 3717.

https://doi.org/10.1182/blood.V126.23.3717.3717

Published: 2015

Journal Articles

FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., Andre C Schuh, MD FRCPC, Mark D Minden, MDPhD, Aaron D Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MRCP, FRCPC, MPH, Naheed Alam, MBBS, MD, Andrzej Lutynski, MD, Amr Rostom, MD CFPC, Anna Rydlewski, MD, Karen Yee, MD

Blood (2014) 124 (21): 5285.

https://doi.org/10.1182/blood.V124.21.5285.5285

Published: 2014

NARROW

Patients Who Are Refractory to Ida-FLAG As Initial Induction Chemotherapy for AML Have Persistence of the Dominant Genetic Mutations and a Poor Clinical Outcome

The Utility of Early Broncholaveolar Lavage in Prolonged Neutropenic Patients with Pulmonary Nodules

Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Patients Who Are Refractory to Ida-FLAG As Initial Induction Chemotherapy for AML Have Persistence of the Dominant Genetic Mutations and a Poor Clinical Outcome

The Utility of Early Broncholaveolar Lavage in Prolonged Neutropenic Patients with Pulmonary Nodules

Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only